Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Genetics Closes Acquisition of Coelacanth

NEW YORK, July 13 – Lexicon Genetics of The Woodlands, Texas, has closed the deal to acquire Coelacanth in a stock transaction valued at $32 million.

Under the terms of the final merger agreement announced Thursday, Lexicon will distribute 2,918,991 shares of common stock to Coelacanth stockholders. The deal is based on Lexicon’s average closing price of $10.9625 per share during the 30 days ending three days prior to the effective date of the merger.

Coelacanth uses proprietary chemistry technologies to discover new chemical entities for drug development. The newly acquired company will make up the core of Lexicon’s new division, Lexicon Pharmaceuticals, which will be based in Princeton, N.J. 

Lexicon Pharmaceuticals will combine Lexicon's defined targets from the human genome with Coelacanth chemistry technologies to discover new drugs. 

Established in 1996, Coelacanth has screening libraries and an industrialized medicinal chemistry platform to create drug development candidates.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.